MAINTAIN (Mucosal AblatIoN Therapy After INcretins)
The purpose of this study is to assess the effect of gastric fundal mucosal ablation (GFMA) on weight trajectory following discontinuation of once-weekly semaglutide or tirzepatide in adults with obesity. In this study, GFMA will be performed on patients who have experienced \> 10% weight loss with GLP-1 therapy and who plan to discontinue use of GLP-1 medications for the duration of the study.
Subjects aged 21-65 [+8]
Known diagnosis of type I or type II diabetes or a Hemoglobin A1c > 6.5% at time... [+15]